Nevro Goes Back to Court With New Patent Infringement Lawsuit

Facebook Twitter Plusone Pinterest Linkedin Tumblr Digg Email

gavelNevro, a global medical equipment company researching and developing solutions to chronic pain, has filed a patent infringement lawsuit against Boston Scientific.

The lawsuit alleges that Boston Scientific infringed on several patents related to Nevro’s Senza and HF10 spinal cord stimulation systems. Nevro is seeking preliminary and permanent injunctive relief against further infringement.

This isn’t the first time Nevro has been in court with Boston Scientific, either. Considering that patent lawsuits have increased from 500 to over 3,000 annually, the multiple lawsuits aren’t surprising. The companies were in court last November as a result of two petitions for inter partes review. Nevro was able to come out on top in that case.

The reviews were declined last November. According to Nevro, “Boston Scientific failed to establish a reasonable likelihood of showing that even one of the challenged claims of the ‘102 patent was invalid.”

The very patent that Boston Scientific requested for review is one of the several involved in Nevro’s newest lawsuit.

In a press release, Nevro’s president and CEO, Rami Elghandour, recalled the company’s origin story, explaining that it was founded in an effort to “develop meaningful advances in the treatment of chronic pain to improve patients’ lives.” In addition, he went into the importance of intellectual property and why the company is so dedicated to protecting it.

“We are committed to ensuring continued innovation in health sciences by protecting our intellectual property,” Elghandour said.

The two biggest components of Nevro’s newest lawsuit are its Senza device and the previously mentioned patent no. 8,359,102. The Senza device is designed to help avoid the sensation known as “parasthesia” by delivering up to 10,000 Hz to the spine. It won pre-market approval from the FDA earlier this year.

Patent no. 8,359,102, on the other hand, deals with directly inhibiting pain. The process is described in the patent as delivering “Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects.”

Facebook Twitter Plusone Pinterest Linkedin Tumblr Digg Email